Recently, the domestic stock market is bullish, but among the top 300 stocks that individual investors have net bought this year, 62.7% (188 stocks) have current prices lower than the average purchase price (purchase transaction amount ÷ transaction volume). This means that many individual investors are in a loss evaluation period.
On the 18th, ChosunBiz calculated the average yield for the 300 KOSPI and KOSDAQ stocks (excluding SPACs) that have seen the largest personal net purchases this year, finding that it was -3.9% based on the previous day's closing price. This contrasts with the KOSPI and KOSDAQ indexes, which have risen by 22.96% and 14.37%, respectively, since the beginning of the year.
The stock with the highest average loss rate among individual net purchase stocks was Bridge Biotherapeutics. Individuals have net purchased 27.1 billion won worth of Bridge Biotherapeutics shares this year. The average purchase price per share is 2,110.5 won, which is 65% lower than the previous day's closing price (739 won).
Bridge Biotherapeutics has been conducting Phase 2 clinical trials for its candidate drug for idiopathic pulmonary fibrosis, "BBT-877." However, following results that failed to secure efficacy in April, the stock price plummeted. The stock price, which had risen to 9,280 won due to expectations for new drug development, is currently below one-tenth of that level.
There also appear to be many investors who suffered losses after investing in political theme stocks during the 21st presidential election period. Stocks of companies such as Hyungji Global, LK CHEM, Orient Precision Industries, and Sangji Construction soared as theme stocks but have now returned to pre-election levels.
The battery sector, favored by individuals, has also seen high average loss rates due to the deepening chasm in electric vehicle demand. Company stocks like Kumyang, Enchem, and Ecopro, which have seen net purchases exceeding 100 billion won this year, have average loss rates around 40%. Notably, Kumyang has been in a trading suspension since March after receiving an "opinion rejection" on its audit report.
Some stocks are showing evaluation gains. GemVax, which has seen net purchases of 26 billion won, has an average purchase price (32,775 won) that is 112% higher than the previous day's closing price (69,500 won). The stock price surged after GemVax's progressive supranuclear palsy (PSP) treatment drug, "GV1001," received consecutive designations as an orphan drug from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) last month.
The biotech stocks D&D Pharmatech and Curiox Biosystems also had high average revenue rates of 101.4% and 80.2%, respectively. D&D Pharmatech recently demonstrated the efficacy of its metabolic disorder fatty liver drug "DD01" in Phase 2 clinical trials in the United States. Curiox Biosystems continues to see growth expectations for its cell analysis process automation platform.
Doosan common and preferred stocks (Doosan Pref) also had high average revenue rates of 75.2% and 70.5%, respectively. This is due to expectations for a reevaluation of the holding company under the new government, as Doosan's electronic business group supplies its core product, Copper Clad Laminate (CCL), to NVIDIA. The stock price of its subsidiary Doosan Enerbility has also surged thanks to the "nuclear renaissance."
In addition, companies such as Peptron, GI Innovation, Mirae Asset Securities, Woori Technology, Tomocube, KoMiCo, Hanwha Ocean, and HD Hyundai Electric also had average revenue rates exceeding the increases in the KOSPI and KOSDAQ indexes.
Despite rising uncertainties, such as soaring international oil prices due to the Israel-Iran conflict, the domestic stock market is showing solid trends as foreign capital flows in.
However, forecasts suggest that stock market movements may become more pronounced depending on the results of the Federal Open Market Committee (FOMC) regular meeting on the 19th. Joain, a researcher at Samsung Securities, said, "With the likelihood of a freeze on the benchmark interest rate in this meeting, the key will be whether there will be changes to the dot plot, which reflected two interest rate cuts within the year."